What happened
Samsung Biologics updated a previously disclosed supply contract, now worth US$365M, about 105.89% of its recent annual revenue, running through Dec 2028.
For context, this single contract equals about 105.89% of the company's most recent annual revenue.
| Counterparty | Disclosed |
|---|---|
| Contract value | US$365M |
| vs. recent revenue | 105.89% |
| Through | Dec 2028 (from Apr 2018) |
| Filed | 2026-09-10, [Amended] Supply contract signed |
| Source | DART rcept 20260910800393 → open original filing |
Source: DART. Information only, not investment advice.